Effects of ADHD Medications on Male Reproductive Function: A Systematic Review of In Vivo Mammalian Evidence.
- 1Scientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.
- 2Department of Clinical and Experimental Pathology, Wroclaw Medical University, Marcinkowskiego 1, 50-368 Wroclaw, Poland.
- 3Department of Forensic Medicine, Division of Molecular Techniques, Wroclaw Medical University, Sklodowskiej-Curie 52, 50-369 Wroclaw, Poland.
Abstract
Long-term treatment with attention-deficit/hyperactivity disorder (ADHD) medications may begin before reproductive maturity, but their effects on male reproductive health remain uncertain. We systematically evaluated controlled in vivo mammalian evidence on male reproductive effects of medications used for ADHD, including the consistency, timing, reversibility, and certainty of reported associations. PubMed/MEDLINE, Embase, and Scopus were searched from inception to 8 August 2026. Eligible studies were English-language, controlled in vivo mammalian experiments evaluating a prespecified ADHD medication and at least one male reproductive outcome. Human, in-vitro-only, uncontrolled, conference-abstract, and preprint reports were excluded. Risk of bias was independently assessed by two reviewers using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool, and certainty was evaluated using an adapted preclinical Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Results were grouped by drug and nine prespecified outcome domains and synthesized narratively. Meta-analysis was not performed because of substantial methodological and outcome heterogeneity. Twenty-two studies were included: 19 evaluated methylphenidate (MPH), two clonidine, and one lisdexamfetamine (LDX); 17 were conducted in rats, four in mice, and one in rhesus macaques. During active MPH exposure, adverse changes predominated in spermatogenesis, sperm quantity or quality, testicular or epididymal microstructure, testosterone, and apoptotic or inflammatory markers. Findings after drug-free follow-up were more often neutral, mixed, or partially reversible. Possible persistent sperm DNA fragmentation and adverse paternal embryonic outcomes were reported but were based on few studies with clustering concerns. Clonidine studies indicated altered epididymal contractility and transport, whereas the single high-dose LDX study reported adverse sperm, testicular, endocrine, DNA-fragmentation, and inflammatory findings. Risk-of-bias assessments were dominated by unclear judgments. None of the 18 drug-by-outcome-domain bodies of evidence reached high or moderate certainty; all were rated as very low certainty. Evidence was limited by small samples, heterogeneous species, developmental stages, doses, routes, exposure durations and assays, incomplete numerical reporting, serious indirectness to therapeutic use in men, and sparse replication outside MPH. ADHD medications, particularly MPH during active exposure, show a possible male reproductive toxicity signal in animal models, but the evidence does not permit quantitative risk estimation or class-wide or clinical conclusions. Better-controlled, exposure-validated animal studies and prospective human cohorts are needed.
Related
- Male Reproductive Disorders Associated with Antiseizure Medications: Evidence from Meta-Analysis and FAERS Pharmacovigilance Study
- Beyond the Biomarkers: Gestation-Dependent Roles of sFLT-1 and PlGF in Human and Non-Human Mammalian Placental Development and Function.
- Dissecting the pro-neurogenic effects of monoaminergic medications used to treat depression: a systematic review and meta-analysis
- Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
- Accelerated Approvals and Clinical Evidence for Medications for Children
BibTeX
@article{wojtysiak2026effects,
title = {{Effects of ADHD Medications on Male Reproductive Function: A Systematic Review of In Vivo Mammalian Evidence.}},
author = {Kacper Wojtysiak and Zuzanna Ratka and Agnieszka Chłopaś-Konowałek},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198492},
url = {https://europepmc.org/article/MED/42883740},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effects of ADHD Medications on Male Reproductive Function: A Systematic Review of In Vivo Mammalian Evidence.
AU - Kacper Wojtysiak
AU - Zuzanna Ratka
AU - Agnieszka Chłopaś-Konowałek
PY - 2026
DA - 2026/09/23
JO - International journal of molecular sciences
DO - 10.3390/ijms27198492
UR - https://europepmc.org/article/MED/42883740
AB - Long-term treatment with attention-deficit/hyperactivity disorder (ADHD) medications may begin before reproductive maturity, but their effects on male reproductive health remain uncertain. We systematically evaluated controlled in vivo mammalian evidence on male reproductive effects of medications used for ADHD, including the consistency, timing, reversibility, and certainty of reported associations. PubMed/MEDLINE, Embase, and Scopus were searched from inception to 8 August 2026. Eligible studies were English-language, controlled in vivo mammalian experiments evaluating a prespecified ADHD medication and at least one male reproductive outcome. Human, in-vitro-only, uncontrolled, conference-abstract, and preprint reports were excluded. Risk of bias was independently assessed by two reviewers using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool, and certainty was evaluated using an adapted preclinical Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Results were grouped by drug and nine prespecified outcome domains and synthesized narratively. Meta-analysis was not performed because of substantial methodological and outcome heterogeneity. Twenty-two studies were included: 19 evaluated methylphenidate (MPH), two clonidine, and one lisdexamfetamine (LDX); 17 were conducted in rats, four in mice, and one in rhesus macaques. During active MPH exposure, adverse changes predominated in spermatogenesis, sperm quantity or quality, testicular or epididymal microstructure, testosterone, and apoptotic or inflammatory markers. Findings after drug-free follow-up were more often neutral, mixed, or partially reversible. Possible persistent sperm DNA fragmentation and adverse paternal embryonic outcomes were reported but were based on few studies with clustering concerns. Clonidine studies indicated altered epididymal contractility and transport, whereas the single high-dose LDX study reported adverse sperm, testicular, endocrine, DNA-fragmentation, and inflammatory findings. Risk-of-bias assessments were dominated by unclear judgments. None of the 18 drug-by-outcome-domain bodies of evidence reached high or moderate certainty; all were rated as very low certainty. Evidence was limited by small samples, heterogeneous species, developmental stages, doses, routes, exposure durations and assays, incomplete numerical reporting, serious indirectness to therapeutic use in men, and sparse replication outside MPH. ADHD medications, particularly MPH during active exposure, show a possible male reproductive toxicity signal in animal models, but the evidence does not permit quantitative risk estimation or class-wide or clinical conclusions. Better-controlled, exposure-validated animal studies and prospective human cohorts are needed.
SN - 1422-0067
ER -